阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性  

Efficacy and safety of apatinib with chemotherapy in treatment of advanced breast cancer

作　　者：龚子永 丁敏[1] 侯建新 GONG Ziyong;DING Min;HOU Jianxin(Department of Galactophore,Xinxiang First People’s Hospital,Xinxiang 453000,He’nan,China)

机构地区：[1]新乡市第一人民医院乳腺科,河南新乡4530000

出　　处：《癌症进展》2020年第20期2095-2098,共4页Oncology Progress

摘　　要：目的探讨阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性。方法根据治疗方法的不同将70例晚期乳腺癌患者分为联合组和化疗组,每组35例,化疗组患者采用紫杉醇联合卡铂治疗,联合组患者在化疗组的基础上给予阿帕替尼治疗。比较两组患者的近期疗效(总有效率和疾病控制率)、生化指标[血清血小板第4因子(PF4)和中期因子(MK)水平]、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)评分]、不良反应发生情况及3年生存情况。结果治疗后联合组患者的总有效率和疾病控制率分别为37.14%和68.57%,分别高于化疗组的14.29%和42.86%,差异均有统计学意义(P<0.05)。治疗后,两组患者的血清PF4、MK水平均低于本组治疗前,EORTC QLQ-C30评分均高于本组治疗前,且联合组患者的血清PF4、MK水平均低于化疗组,EORTC QLQ-C30评分高于化疗组,差异均有统计学意义(P<0.05)。两组患者上消化道反应、中性粒细胞减少、蛋白尿的发生情况比较,差异均无统计学意义(P>0.05)。随访3年,联合组患者的总生存率为65.71%(23/35),高于化疗组患者的45.71%(16/35),差异有统计学意义(P<0.05)。结论阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性均较好,其可能通过抑制血清PF4、MK水平发挥治疗效果,进而提高患者的生活质量,改善患者预后。Objective To explore the efficacy and safety of apatinib with chemotherapy in treatment of advanced breast cancer.Method 70 patients with advanced breast cancer were divided into combination group(n=35)and chemotherapy group(n=35).The chemotherapy group was treated with paclitaxel and carboplatin,and the combination group was treated with apatinib on the basis of chemotherapy group.The short term efficacy(overall response rate and disease control rate),biochemical parameters[serum platelet factor 4(PF4)and midkine(MK)],quality of life[scores of European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],adverse reactions,and 3-year survival were compared between the two groups.Result After treatment,there were significant differences for the overall response rate(37.14%vs 14.29%)and disease control rate(68.57%vs 42.86%)between the combination group and the chemotherapy group(P<0.05).After treatment,the serum PF4,MK of the two groups were lower and the EORTC QLQ-C30 scores of the two groups were higher than that before treatment,the serum PF4,MK of the combination group were lower and the EORTC QLQ-C30 scores were higher than that of the chemotherapy group,and the differences were statistically significant(P<0.05).There were no significant differences in upper gastrointestinal reaction,neutropenia and proteinuria between the two groups(P>0.05).Followed up for 3 years,the overall survival rate of combination group was 65.71%(23/35),which was higher than 45.71%(16/35)of the chemotherapy group(P<0.05).Conclusion Apatinib with chemotherapy is effective and safe in treatment of advanced breast cancer,which can take effect by inhibiting serum PF4 and MK,thus improving the quality of life and prognosis.

关 键 词：晚期乳腺癌 阿帕替尼 化疗 近期疗效 预后 

分 类 号：R737.9[医药卫生—肿瘤]